The content on this site is intended for healthcare professionals only
Prof Franco Locatelli talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about whether it is possible to reduce the intensity of frontline therapy.
Prof Locatelli outlines the results of a trial he presented on behalf of Prof Martin Schrappe.
He states that unfortunately a reduction in chemotherapy intensity was associated with an increased risk of leukaemia recurrence.
He adds, however, that for some subset groups such as children under the age of 7, the reduction of therapy was not associated with an increase of recurrence.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL
Multiple Myeloma: evolving paradigm - Panel Discussion
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ASCO 2024: Lung cancer highlights
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
The evolving paradigm in management of Multiple Myeloma
